Final cohort results from Phio's PH-762 Phase 1b skin-cancer trial were favorable, with 100% tumor clearance in one patient, greater than 90% in a second, and greater than 50% in a third, coupled with a favorable safety review at the maximum dose. The stock jumped on this news, before giving back more than all of the day's gain. We believe the announcement of a warrant exercise weighed on the stock price. In addition, David H. Deming was named last week as Lead Independent Director, bringing biopharma investment-banking experience to the forefront. Phio is expected to release earnings and provide a business update this month. The company does not typically announce the date ahead of time or hold an earnings call. We maintain our estimates for 3Q:25 earnings, and raise our estimates going forward into 4Q;25 and 2026, as the financing we projected in 1Q:26 has been pulled forward. We continue to assign a High-Risk rating, given the early stage of commercialization and history of net losses.